V. Menendez et al., Usefulness of urinary nuclear matrix protein 22 (NMP22) as a marker for transtional cell carcinoma of the bladder, ANTICANC R, 20(2B), 2000, pp. 1169-1172
Objectives: The purpose of this study was to evaluate an immunoassay for ur
inary nuclear matrix protein, NMP22, as a novel marker for urothelial cance
r. Patients and Methods: NMP22 values were determined for 71 patients and 2
1 healthy volunteers. Each subject provided a single (3 voids) urine sample
for analysis at the time of entry into the study. Each sample was assayed
for levels of NMP22. Results: When the cut-off value was set at 10 U/ml, th
e positive rare for urinary NMP22 in bladder cancer was 37.8% (17 out of 45
), whereas that in post-treatment cases and benign diseases was 30.8% (8 ou
t of 26) compared to 14.3% (3 out of 21) for healthy volunteers. This cut-o
ff value provided a sensitivity of 37.8% and a specificity of 80.9%. In the
bladder cancer group, NMP22 levels were related to tumor size, shape, grad
e and stage. Conclusions: Despite the many reports that suggest NMP22 as a
promising urinary marker for monitoring transitional cell carcinoma, this s
tudy does not support its usefulness as a substitute tool for urinary cytol
ogy in the control of bladder tumors.